$16,552.34 consulting Payment -- Johnson & Johnson to Dr. Jeffrey Campbell

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Johnson & Johnson made a $16.6K consulting payment to Jeffrey Campbell, a Internal Medicine specialist in Jersey City, NJ. The payment was associated with Farxiga. The payment of $16,552.34 to Dr. Jeffrey Campbell for consulting services related to Farxiga is a significant amount. The payment was made by Johnson & Johnson, a major pharmaceutical company, for consulting services. The payment occurred on April 6, 2025, and was for consulting fees.

Patient Guidance: What This Payment Means for You

This payment is for consulting services related to a medication. It is important to understand the nature of any financial relationships between healthcare providers and pharmaceutical companies. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Consulting fees can vary widely depending on the scope of work, the physician's expertise, and the pharmaceutical company's needs. This amount may be within the typical range for specialized consulting services in Internal Medicine.

Regulatory Context: Sunshine Act Requirements

Payments to physicians for consulting services are subject to disclosure under the Open Payments program, requiring transparency in financial relationships between the healthcare industry and medical professionals.

Related Topics

This payment is related to the following healthcare transparency topics:

• consulting-fee
• pharmaceutical-payment
• internal-medicine
• farxiga
• johnson-johnson
• physician-payment

Understanding consulting Payments

Consulting payments are made when pharmaceutical companies hire physicians as advisors or consultants. This can include serving on advisory boards, providing expert medical opinions on drug development or marketing strategies, and reviewing clinical data. Consulting is one of the most common forms of pharmaceutical payment to physicians and can range from a few hundred dollars for a brief consultation to tens of thousands of dollars for ongoing advisory relationships.

Frequently Asked Questions About This Payment

What was this $16.6K payment for?

This was a consulting payment of $16.6K from Johnson & Johnson to Jeffrey Campbell, categorized as "Consulting Fee". It was associated with Farxiga. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Jeffrey Campbell accept pharmaceutical money?

Yes, Jeffrey Campbell received this $16.6K payment from Johnson & Johnson. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Jeffrey Campbell's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this consulting payment?

A consulting payment of $16.6K may reflect legitimate advisory services the physician provides. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Internal Medicine?

To compare this payment against Internal Medicine averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Internal Medicine physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Jeffrey Campbell's relationship with Johnson & Johnson?

The payment is specifically for consulting services, not for speaking engagements or meals. This $16.6K consulting payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Internal Medicine?

The drug associated with this payment is Farxiga, indicating a focus on a specific therapeutic area.

What should patients do after learning about this payment?

This payment is for consulting services related to a medication. It is important to understand the nature of any financial relationships between healthcare providers and pharmaceutical companies.

What else should I know about this consulting payment?

Dr. Campbell's specialty is Internal Medicine, which aligns with the potential use of Farxiga.

Related Reports

• View Dr. Jeffrey Campbell's full payment report
• Johnson & Johnson full spending report
• Browse all Internal Medicine payments
• Browse all payments in New Jersey
• Search for other payments